C79
Secondary malignant neoplasm of other and unspecified sites
Category C79 identifies secondary malignant neoplasms, commonly known as metastases, that have spread from a primary site to specific anatomical locations not classified elsewhere in the C77 (lymph nodes) or C78 (respiratory and digestive organs) ranges. Metastasis occurs when cancer cells detach from the primary tumor and travel through the circulatory or lymphatic systems to seed new growth in distant organs. This category includes common metastatic targets such as the skeletal system, the central nervous system (brain and spinal cord), the adrenal glands, and the skin. The presence of secondary neoplasms typically indicates Stage IV (advanced) disease, necessitating systemic therapeutic approaches like chemotherapy, immunotherapy, or targeted molecular therapy, alongside localized palliative interventions.
Clinical Symptoms
- Localized bone pain and tenderness
- Pathological fractures occurring with minimal trauma
- Headaches, seizures, or focal neurological deficits
- Cognitive changes or personality shifts
- New or changing skin nodules or lesions
- Unintentional and rapid weight loss
- Generalized fatigue and malaise
- Symptoms of hypercalcemia (confusion, polyuria, constipation)
- Radicular pain from spinal cord compression
- Abdominal or flank pain if adrenal or renal involvement
Common Causes
- Hematogenous spread from primary lung adenocarcinoma
- Metastatic dissemination of primary breast carcinoma
- Lymphatic or hematogenous spread of primary prostate cancer
- Advanced stage renal cell carcinoma
- Aggressive malignant melanoma
- Primary colorectal cancer with systemic spread
- Late-stage presentation of primary malignancies with high metastatic potential
Documentation & Coding Tips
Always specify the precise anatomical site of the secondary neoplasm to ensure code specificity at the fourth or fifth character level.
Example: Patient with established metastatic disease presents for evaluation of new back pain. Radiographic imaging of the spine reveals a lytic lesion at the T10 vertebra. Documentation confirms secondary malignant neoplasm of the bone (C79.51) arising from the primary lung adenocarcinoma (C34.11). Management includes initiation of denosumab and referral to radiation oncology for palliative care.
Billing Focus: Identify the specific bone or organ involved rather than using a general body region to support C79.51 vs C79.9.
Document the relationship between the secondary site and the primary site, or note if the primary site is unknown or has been previously excised.
Example: Follow-up for patient with personal history of malignant melanoma of the right trunk, excised 2022 (Z85.820). Current PET scan indicates new hypermetabolic activity in the right adrenal gland. Impression: Secondary malignant neoplasm of the right adrenal gland (C79.71). Plan: Biopsy to confirm metastatic melanoma versus primary adrenal cortical carcinoma.
Billing Focus: Differentiates between an active primary (C00-C76) and a history of primary (Z85) while coding the active secondary site (C79).
Specify laterality for secondary neoplasms involving paired organs such as the kidneys, adrenal glands, or ovaries.
Example: A 62-year-old female with primary left breast cancer (C50.412) now presents with pelvic pain. Ultrasound and CT indicate a solid mass in the right ovary. Clinical assessment: Secondary malignant neoplasm of the right ovary (C79.61). Patient scheduled for oophorectomy.
Billing Focus: Use of the sixth character for laterality (1 for right, 2 for left) is required for C79.6 and C79.7 subcategories.
Distinguish between direct extension of a primary tumor and true metastatic spread to a distant site.
Example: Oncology consultation for primary cervical cancer (C53.9) with evidence of direct extension into the vaginal wall and bladder base. This is coded as primary malignancy of those sites if contiguous, rather than secondary metastasis (C79), unless distant sites like the lungs (C78.00) are involved.
Billing Focus: Correctly applying the ICD-10-CM guidelines for contiguous sites versus metastatic spread prevents upcoding or downcoding errors.
Clearly document any associated complications of the secondary neoplasm, such as pathological fractures or spinal cord compression.
Example: Patient with secondary malignant neoplasm of the lumbar spine (C79.51) from primary prostate cancer (C61). Patient presents with acute onset of lower extremity weakness. MRI shows vertebral body collapse at L3. Diagnosis: Pathological fracture in neoplastic disease (M84.58xA) due to spinal metastasis.
Billing Focus: Sequencing the complication (e.g., pathological fracture) as the primary diagnosis followed by the secondary neoplasm (C79.51) is required for acute injury encounters.
Relevant CPT Codes
-
99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a moderate level of medical decision making
Typically used for managing metastatic disease where complex treatment options and systemic progress must be evaluated.
-
99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a high level of medical decision making
Reserved for patients with advanced secondary neoplasms with severe complications or toxicities from treatment.
-
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
Standard procedure for treating secondary neoplasms with systemic cytotoxic agents.
-
77014 - Computed tomography guidance for radiotherapy fields localization
Essential for palliative radiation of secondary sites such as bone or brain.
-
38500 - Biopsy or excision of lymph node(s); open, superficial
Necessary to confirm if a palpable node represents a secondary malignant neoplasm.
-
78815 - Positron emission tomography (PET) with concurrently acquired computed tomography (CT)
Gold standard for staging and identifying unknown secondary sites (C79).
-
99204 - Office or other outpatient visit for the evaluation and management of a new patient, which requires a moderate level of medical decision making
Initial consultation for a patient newly diagnosed with metastatic disease.
-
20240 - Biopsy, bone, open; superficial
Used to confirm suspected secondary malignant neoplasm of the bone (C79.51).
-
96372 - Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
Used for hormonal therapies or bone-strengthening agents (e.g., denosumab) in metastatic cancer.
-
61140 - Burr hole(s) or trephine; with biopsy of brain or intracranial lesion
Required to confirm metastasis in patients with a secondary malignant neoplasm of the brain.
Related Diagnoses
- C77.0 - Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
- C78.01 - Secondary malignant neoplasm of right lung
- C79.31 - Secondary malignant neoplasm of brain
- C79.51 - Secondary malignant neoplasm of bone
- C79.61 - Secondary malignant neoplasm of right ovary
- C79.81 - Secondary malignant neoplasm of breast
- C80.0 - Disseminated malignant neoplasm, unspecified
- C80.1 - Malignant (primary) neoplasm, unspecified
- Z85.3 - Personal history of malignant neoplasm of breast
- Z51.11 - Encounter for antineoplastic chemotherapy
- C79.72 - Secondary malignant neoplasm of left adrenal gland
- C79.2 - Secondary malignant neoplasm of skin